RT Journal Article
SR Electronic
T1 Clinical evaluation of BD Veritor<sup>™</sup> SARS-CoV-2 point-of-care test performance compared to PCR-based testing and versus the Sofia<sup>®</sup> 2 SARS Antigen point-of-care test
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.01.20185777
DO 10.1101/2020.09.01.20185777
A1 Young, Stephen
A1 Taylor, Stephanie N.
A1 Cammarata, Catherine L.
A1 Roger-Dalbert, Celine
A1 Montano, Amanda
A1 Griego-Fullbright, Christen
A1 Burgard, Cameron
A1 Fernandez, Catherine
A1 Eckert, Karen
A1 Andrews, Jeffrey C.
A1 Ren, Huimiao
A1 Allen, Joseph
A1 Ackerman, Ronald
A1 Cooper, Charles K.
YR 2020
UL http://medrxiv.org/content/early/2020/09/04/2020.09.01.20185777.abstract
AB Objectives The clinical performance of the BD Veritor™ System for Rapid Detection of SARS-CoV-2 antigen (Veritor), a chromatographic immunoassay that detects the SARS-CoV-2 nucleocapsid antigen as a point-of-care test, was evaluated on nasal specimens from individuals with COVID-19 symptoms.Methods and Materials Two studies were completed to determine clinical performance. In the first study, nasal specimens and either nasopharyngeal or oropharyngeal specimens from 251 participants with COVID-19 symptoms (≤7 days from symptom onset [DSO]), ≥18 years of age, were utilized to compare Veritor with the Lyra® SARS-CoV-2 PCR Assay (Lyra). In the second study, nasal specimens from 361 participants with COVID-19 symptoms (≤5 DSO), ≥18 years of age, were utilized to compare performance of Veritor to that of the Sofia® 2 SARS Antigen FIA test (Sofia 2). Positive, negative, and overall percent agreement (PPA, NPA, and OPA, respectively) were the primary outcomes.Results In study 1, PPA for Veritor, compared to Lyra, ranged from 81.8%-87.5% for 0-1 through 0-6 DSO ranges. In study 2, Veritor had a PPA, NPA, and OPA of 97.4%, 98.1%, and 98.1%, respectively, with Sofia 2. Discordant analysis showed one Lyra positive missed by Veritor and five Lyra positives missed by Sofia 2; one Veritor positive result was negative by Lyra.Conclusions Veritor met FDA-EUA acceptance criteria for SARS-CoV-2 antigen testing (≥80% PPA point estimate) for the 0-5 and 0-6 DSO ranges. Veritor and Sofia 2 showed a high degree of agreement for SARS-CoV-2 detection. The Veritor test should facilitate rapid and reliable results for COVID-19 diagnosis utilizing easy-to-collect nasal swabs.Summary The BD Veritor SARS-CoV-2 antigen test met FDA-EUA acceptance criteria for SARS-CoV-2 antigen testing for subjects with COVID-19 symptoms (0-5 days post-onset). BD Veritor and Quidel Sofia 2 antigen tests had good agreement for SARS-CoV-2 detection; discordant analysis favored Veritor.Competing Interest StatementThe authors disclose the following conflicts of interest: CRD, CF, KE, JCA, HR, and CKC are employees of Becton, Dickinson and Company; SY, None; CC, None; AM, None; CGF, None; CB, None; JA, None; RA, CEO and PI of Comprehensive Clinical Research LLCClinical TrialRegistration of this study at ClinicalTrials.gov was not obtained as it did not fulfill the applicable minimum medical device clinical trial requirement criteria as per the Food and Drug Administration Amendments Act. Specifically, this study did not assess health outcomes associated with the use of this assay.Funding StatementThis study was funded by Becton, Dickinson and Company; BD Life Sciences-Integrated Diagnostics Solutions. Non-BD employee authors received research funds as part of this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Continuing review approval: Advarra IRB-CR00170042-Approval date: 3 Dec 2019 Continuing review Becton Dickinson - BDX-GSCP01, Becton Dickinson Program for Collection of BioSpecimens (Pro00015576) study 1 COVID approval notice: Advarra IRB-MOD00683499-Approval date: 29 May 2020 Becton Dickinson - BDX-GSCP01, Becton Dickinson Program for Collection of BioSpecimens (Pro00015576) Study 2 COVID approval notice: Advarra IRB-MOD00717838-Approval date: 13 Jul 2020 Becton Dickinson - BDX-GSCP01, Becton Dickinson Program for Collection of BioSpecimens (Pro00015576)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study should be requested from Dr. Charles K. Cooper. Contact Devin.Gary{at}bd.com